These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36297433)

  • 1. Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study.
    Pérez-Carrillo L; Aragón-Herrera A; Giménez-Escamilla I; Delgado-Arija M; García-Manzanares M; Anido-Varela L; Lago F; Martínez-Dolz L; Portolés M; Tarazón E; Roselló-Lletí E
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SLC9C2 Gene Product (Na
    Gardner CC; James PF
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes.
    Iborra-Egea O; Santiago-Vacas E; Yurista SR; Lupón J; Packer M; Heymans S; Zannad F; Butler J; Pascual-Figal D; Lax A; Núñez J; de Boer RA; Bayés-Genís A
    JACC Basic Transl Sci; 2019 Nov; 4(7):831-840. PubMed ID: 31998851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis.
    Chung CC; Lin YK; Chen YC; Kao YH; Yeh YH; Trang NN; Chen YJ
    Cardiovasc Diabetol; 2023 Feb; 22(1):27. PubMed ID: 36747205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
    Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
    Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin inhibits Na
    Trum M; Riechel J; Lebek S; Pabel S; Sossalla ST; Hirt S; Arzt M; Maier LS; Wagner S
    ESC Heart Fail; 2020 Dec; 7(6):4429-4437. PubMed ID: 32946200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na
    Baker HE; Tune JD; Mather KJ; Blaettner BS; Clark HE; Li F; Li X; Kowala MC; Fliegel L; Goodwill AG
    Int J Cardiol; 2022 Sep; 363():138-148. PubMed ID: 35753619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
    Oh J; Lee SH; Lee CJ; Kang SM
    Korean Circ J; 2021 May; 51(5):399-408. PubMed ID: 33975387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.
    Uthman L; Baartscheer A; Schumacher CA; Fiolet JWT; Kuschma MC; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Front Physiol; 2018; 9():1575. PubMed ID: 30519189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells.
    Chen S; Schumacher CA; Van Amersfoorth SCM; Fiolet JWT; Baartscheer A; Veldkamp MW; Coronel R; Zuurbier CJ
    Front Physiol; 2023; 14():1179131. PubMed ID: 37565139
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a.
    Goerg J; Sommerfeld M; Greiner B; Lauer D; Seckin Y; Kulikov A; Ivkin D; Kintscher U; Okovityi S; Kaschina E
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
    Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria.
    Xu Y; Zhang C; Jiang K; Yang X; Chen F; Cheng Z; Zhao J; Cheng J; Li X; Chen X; Zhou L; Duan H; Huang Y; Xiang Y; Li J
    Acta Pharm Sin B; 2023 Apr; 13(4):1671-1685. PubMed ID: 37139418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
    Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
    Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
    Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Cardiol; 2021 Jul; 150():65-68. PubMed ID: 34001339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.